Serveur d'exploration sur le Covid à Stanford

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients.

Identifieur interne : 000801 ( Main/Exploration ); précédent : 000800; suivant : 000802

Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients.

Auteurs : Jeffrey E. Gold ; William H. Baumgartl [États-Unis] ; Ramazan A. Okyay [Turquie] ; Warren E. Licht [États-Unis] ; Paul L. Fidel [États-Unis] ; Mairi C. Noverr [États-Unis] ; Larry P. Tilley [États-Unis] ; David J. Hurley [États-Unis] ; Balázs Rada [États-Unis] ; John W. Ashford [États-Unis]

Source :

RBID : pubmed:33219096

Descripteurs français

English descriptors

Abstract

The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against coronavirus disease 2019 (COVID-19). Our aim was to determine whether any MMR IgG titers are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with MMR II. We divided 80 subjects into two groups, comparing MMR titers to recent COVID-19 severity levels. The MMR II group consisted of 50 subjects who would primarily have MMR antibodies from the MMR II vaccine, and a comparison group of 30 subjects consisted of those who would primarily have MMR antibodies from sources other than MMR II, including prior measles, mumps, and/or rubella illnesses. There was a significant inverse correlation (rs  = -0.71, P < 0.001) between mumps virus titers (mumps titers) and COVID-19 severity within the MMR II group. There were no significant correlations between mumps titers and severity in the comparison group, between mumps titers and age in the MMR II group, or between severity and measles or rubella titers in either group. Within the MMR II group, mumps titers of 134 to 300 arbitrary units (AU)/ml (n = 8) were found only in those who were functionally immune or asymptomatic; all with mild symptoms had mumps titers below 134 AU/ml (n = 17); all with moderate symptoms had mumps titers below 75 AU/ml (n = 11); all who had been hospitalized and had required oxygen had mumps titers below 32 AU/ml (n = 5). Our results demonstrate that there is a significant inverse correlation between mumps titers from MMR II and COVID-19 severity.IMPORTANCE COVID-19 has presented various paradoxes that, if understood better, may provide clues to controlling the pandemic, even before a COVID-19 vaccine is widely available. First, young children are largely spared from severe disease. Second, numerous countries have COVID-19 death rates that are as low as 1% of the death rates of other countries. Third, many people, despite prolonged close contact with someone who is COVID-19 positive, never test positive themselves. Fourth, nearly half of people who test positive for COVID-19 are asymptomatic. Some researchers have theorized that the measles-mumps-rubella (MMR) vaccine may be responsible for these disparities. The significance of our study is that it showed that mumps titers related to the MMR II vaccine are significantly and inversely correlated with the severity of COVID-19-related symptoms, supporting the theorized association between the MMR vaccine and COVID-19 severity.

DOI: 10.1128/mBio.02628-20
PubMed: 33219096
PubMed Central: PMC7686805


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients.</title>
<author>
<name sortKey="Gold, Jeffrey E" sort="Gold, Jeffrey E" uniqKey="Gold J" first="Jeffrey E" last="Gold">Jeffrey E. Gold</name>
<affiliation>
<nlm:affiliation>World Organization, Watkinsville, Georgia, USA jeff_gold@world.org.</nlm:affiliation>
<wicri:noCountry code="subField">USA jeff_gold@world.org.</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Baumgartl, William H" sort="Baumgartl, William H" uniqKey="Baumgartl W" first="William H" last="Baumgartl">William H. Baumgartl</name>
<affiliation wicri:level="2">
<nlm:affiliation>Nevada Spine Center, Las Vegas, Nevada, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Nevada Spine Center, Las Vegas, Nevada</wicri:regionArea>
<placeName>
<region type="state">Nevada</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Okyay, Ramazan A" sort="Okyay, Ramazan A" uniqKey="Okyay R" first="Ramazan A" last="Okyay">Ramazan A. Okyay</name>
<affiliation wicri:level="1">
<nlm:affiliation>Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Kahramanmaraş Sütçü İmam University, Kahramanmaraş</wicri:regionArea>
<wicri:noRegion>Kahramanmaraş</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Licht, Warren E" sort="Licht, Warren E" uniqKey="Licht W" first="Warren E" last="Licht">Warren E. Licht</name>
<affiliation wicri:level="2">
<nlm:affiliation>Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Warren Alpert Medical School of Brown University, Providence, Rhode Island</wicri:regionArea>
<placeName>
<region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Fidel, Paul L" sort="Fidel, Paul L" uniqKey="Fidel P" first="Paul L" last="Fidel">Paul L. Fidel</name>
<affiliation wicri:level="2">
<nlm:affiliation>Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Louisiana State University Health Sciences Center, New Orleans, Louisiana</wicri:regionArea>
<placeName>
<region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Noverr, Mairi C" sort="Noverr, Mairi C" uniqKey="Noverr M" first="Mairi C" last="Noverr">Mairi C. Noverr</name>
<affiliation wicri:level="2">
<nlm:affiliation>Tulane University School of Medicine, New Orleans, Louisiana, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Tulane University School of Medicine, New Orleans, Louisiana</wicri:regionArea>
<placeName>
<region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Tilley, Larry P" sort="Tilley, Larry P" uniqKey="Tilley L" first="Larry P" last="Tilley">Larry P. Tilley</name>
<affiliation wicri:level="2">
<nlm:affiliation>VetMed Consultants, Inc., Santa Fe, New Mexico, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>VetMed Consultants, Inc., Santa Fe, New Mexico</wicri:regionArea>
<placeName>
<region type="state">Nouveau-Mexique</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hurley, David J" sort="Hurley, David J" uniqKey="Hurley D" first="David J" last="Hurley">David J. Hurley</name>
<affiliation wicri:level="2">
<nlm:affiliation>College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>College of Veterinary Medicine, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Rada, Balazs" sort="Rada, Balazs" uniqKey="Rada B" first="Balázs" last="Rada">Balázs Rada</name>
<affiliation wicri:level="2">
<nlm:affiliation>College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>College of Veterinary Medicine, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Ashford, John W" sort="Ashford, John W" uniqKey="Ashford J" first="John W" last="Ashford">John W. Ashford</name>
<affiliation wicri:level="4">
<nlm:affiliation>Stanford University, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Stanford University, Stanford, California</wicri:regionArea>
<placeName>
<region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33219096</idno>
<idno type="pmid">33219096</idno>
<idno type="doi">10.1128/mBio.02628-20</idno>
<idno type="pmc">PMC7686805</idno>
<idno type="wicri:Area/Main/Corpus">000149</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000149</idno>
<idno type="wicri:Area/Main/Curation">000149</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000149</idno>
<idno type="wicri:Area/Main/Exploration">000149</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients.</title>
<author>
<name sortKey="Gold, Jeffrey E" sort="Gold, Jeffrey E" uniqKey="Gold J" first="Jeffrey E" last="Gold">Jeffrey E. Gold</name>
<affiliation>
<nlm:affiliation>World Organization, Watkinsville, Georgia, USA jeff_gold@world.org.</nlm:affiliation>
<wicri:noCountry code="subField">USA jeff_gold@world.org.</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Baumgartl, William H" sort="Baumgartl, William H" uniqKey="Baumgartl W" first="William H" last="Baumgartl">William H. Baumgartl</name>
<affiliation wicri:level="2">
<nlm:affiliation>Nevada Spine Center, Las Vegas, Nevada, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Nevada Spine Center, Las Vegas, Nevada</wicri:regionArea>
<placeName>
<region type="state">Nevada</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Okyay, Ramazan A" sort="Okyay, Ramazan A" uniqKey="Okyay R" first="Ramazan A" last="Okyay">Ramazan A. Okyay</name>
<affiliation wicri:level="1">
<nlm:affiliation>Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Kahramanmaraş Sütçü İmam University, Kahramanmaraş</wicri:regionArea>
<wicri:noRegion>Kahramanmaraş</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Licht, Warren E" sort="Licht, Warren E" uniqKey="Licht W" first="Warren E" last="Licht">Warren E. Licht</name>
<affiliation wicri:level="2">
<nlm:affiliation>Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Warren Alpert Medical School of Brown University, Providence, Rhode Island</wicri:regionArea>
<placeName>
<region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Fidel, Paul L" sort="Fidel, Paul L" uniqKey="Fidel P" first="Paul L" last="Fidel">Paul L. Fidel</name>
<affiliation wicri:level="2">
<nlm:affiliation>Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Louisiana State University Health Sciences Center, New Orleans, Louisiana</wicri:regionArea>
<placeName>
<region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Noverr, Mairi C" sort="Noverr, Mairi C" uniqKey="Noverr M" first="Mairi C" last="Noverr">Mairi C. Noverr</name>
<affiliation wicri:level="2">
<nlm:affiliation>Tulane University School of Medicine, New Orleans, Louisiana, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Tulane University School of Medicine, New Orleans, Louisiana</wicri:regionArea>
<placeName>
<region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Tilley, Larry P" sort="Tilley, Larry P" uniqKey="Tilley L" first="Larry P" last="Tilley">Larry P. Tilley</name>
<affiliation wicri:level="2">
<nlm:affiliation>VetMed Consultants, Inc., Santa Fe, New Mexico, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>VetMed Consultants, Inc., Santa Fe, New Mexico</wicri:regionArea>
<placeName>
<region type="state">Nouveau-Mexique</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hurley, David J" sort="Hurley, David J" uniqKey="Hurley D" first="David J" last="Hurley">David J. Hurley</name>
<affiliation wicri:level="2">
<nlm:affiliation>College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>College of Veterinary Medicine, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Rada, Balazs" sort="Rada, Balazs" uniqKey="Rada B" first="Balázs" last="Rada">Balázs Rada</name>
<affiliation wicri:level="2">
<nlm:affiliation>College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>College of Veterinary Medicine, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Ashford, John W" sort="Ashford, John W" uniqKey="Ashford J" first="John W" last="Ashford">John W. Ashford</name>
<affiliation wicri:level="4">
<nlm:affiliation>Stanford University, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Stanford University, Stanford, California</wicri:regionArea>
<placeName>
<region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">mBio</title>
<idno type="eISSN">2150-7511</idno>
<imprint>
<date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Antibodies, Viral (blood)</term>
<term>Asymptomatic Infections (MeSH)</term>
<term>COVID-19 (immunology)</term>
<term>Convalescence (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunoglobulin G (blood)</term>
<term>Male (MeSH)</term>
<term>Measles-Mumps-Rubella Vaccine (immunology)</term>
<term>Middle Aged (MeSH)</term>
<term>Severity of Illness Index (MeSH)</term>
<term>Vaccination (statistics & numerical data)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Anticorps antiviraux (sang)</term>
<term>Convalescence (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Immunoglobuline G (sang)</term>
<term>Indice de gravité de la maladie (MeSH)</term>
<term>Infections asymptomatiques (MeSH)</term>
<term>Jeune adulte (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Vaccin contre la rougeole, les oreillons et la rubéole (immunologie)</term>
<term>Vaccination (statistiques et données numériques)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Vaccin contre la rougeole, les oreillons et la rubéole</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>COVID-19</term>
<term>Measles-Mumps-Rubella Vaccine</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Anticorps antiviraux</term>
<term>Immunoglobuline G</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en">
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr">
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Asymptomatic Infections</term>
<term>Convalescence</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Convalescence</term>
<term>Femelle</term>
<term>Humains</term>
<term>Indice de gravité de la maladie</term>
<term>Infections asymptomatiques</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Sujet âgé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against coronavirus disease 2019 (COVID-19). Our aim was to determine whether any MMR IgG titers are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with MMR II. We divided 80 subjects into two groups, comparing MMR titers to recent COVID-19 severity levels. The MMR II group consisted of 50 subjects who would primarily have MMR antibodies from the MMR II vaccine, and a comparison group of 30 subjects consisted of those who would primarily have MMR antibodies from sources other than MMR II, including prior measles, mumps, and/or rubella illnesses. There was a significant inverse correlation (
<i>r
<sub>s</sub>
</i>
 = -0.71,
<i>P</i>
 < 0.001) between mumps virus titers (mumps titers) and COVID-19 severity within the MMR II group. There were no significant correlations between mumps titers and severity in the comparison group, between mumps titers and age in the MMR II group, or between severity and measles or rubella titers in either group. Within the MMR II group, mumps titers of 134 to 300 arbitrary units (AU)/ml (
<i>n</i>
 = 8) were found only in those who were functionally immune or asymptomatic; all with mild symptoms had mumps titers below 134 AU/ml (
<i>n</i>
 = 17); all with moderate symptoms had mumps titers below 75 AU/ml (
<i>n</i>
 = 11); all who had been hospitalized and had required oxygen had mumps titers below 32 AU/ml (
<i>n</i>
 = 5). Our results demonstrate that there is a significant inverse correlation between mumps titers from MMR II and COVID-19 severity.
<b>IMPORTANCE</b>
COVID-19 has presented various paradoxes that, if understood better, may provide clues to controlling the pandemic, even before a COVID-19 vaccine is widely available. First, young children are largely spared from severe disease. Second, numerous countries have COVID-19 death rates that are as low as 1% of the death rates of other countries. Third, many people, despite prolonged close contact with someone who is COVID-19 positive, never test positive themselves. Fourth, nearly half of people who test positive for COVID-19 are asymptomatic. Some researchers have theorized that the measles-mumps-rubella (MMR) vaccine may be responsible for these disparities. The significance of our study is that it showed that mumps titers related to the MMR II vaccine are significantly and inversely correlated with the severity of COVID-19-related symptoms, supporting the theorized association between the MMR vaccine and COVID-19 severity.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">33219096</PMID>
<DateCompleted>
<Year>2020</Year>
<Month>12</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised>
<Year>2020</Year>
<Month>12</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">2150-7511</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>11</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2020</Year>
<Month>11</Month>
<Day>20</Day>
</PubDate>
</JournalIssue>
<Title>mBio</Title>
<ISOAbbreviation>mBio</ISOAbbreviation>
</Journal>
<ArticleTitle>Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">e02628-20</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/mBio.02628-20</ELocationID>
<Abstract>
<AbstractText>The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against coronavirus disease 2019 (COVID-19). Our aim was to determine whether any MMR IgG titers are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with MMR II. We divided 80 subjects into two groups, comparing MMR titers to recent COVID-19 severity levels. The MMR II group consisted of 50 subjects who would primarily have MMR antibodies from the MMR II vaccine, and a comparison group of 30 subjects consisted of those who would primarily have MMR antibodies from sources other than MMR II, including prior measles, mumps, and/or rubella illnesses. There was a significant inverse correlation (
<i>r
<sub>s</sub>
</i>
 = -0.71,
<i>P</i>
 < 0.001) between mumps virus titers (mumps titers) and COVID-19 severity within the MMR II group. There were no significant correlations between mumps titers and severity in the comparison group, between mumps titers and age in the MMR II group, or between severity and measles or rubella titers in either group. Within the MMR II group, mumps titers of 134 to 300 arbitrary units (AU)/ml (
<i>n</i>
 = 8) were found only in those who were functionally immune or asymptomatic; all with mild symptoms had mumps titers below 134 AU/ml (
<i>n</i>
 = 17); all with moderate symptoms had mumps titers below 75 AU/ml (
<i>n</i>
 = 11); all who had been hospitalized and had required oxygen had mumps titers below 32 AU/ml (
<i>n</i>
 = 5). Our results demonstrate that there is a significant inverse correlation between mumps titers from MMR II and COVID-19 severity.
<b>IMPORTANCE</b>
COVID-19 has presented various paradoxes that, if understood better, may provide clues to controlling the pandemic, even before a COVID-19 vaccine is widely available. First, young children are largely spared from severe disease. Second, numerous countries have COVID-19 death rates that are as low as 1% of the death rates of other countries. Third, many people, despite prolonged close contact with someone who is COVID-19 positive, never test positive themselves. Fourth, nearly half of people who test positive for COVID-19 are asymptomatic. Some researchers have theorized that the measles-mumps-rubella (MMR) vaccine may be responsible for these disparities. The significance of our study is that it showed that mumps titers related to the MMR II vaccine are significantly and inversely correlated with the severity of COVID-19-related symptoms, supporting the theorized association between the MMR vaccine and COVID-19 severity.</AbstractText>
<CopyrightInformation>Copyright © 2020 Gold et al.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gold</LastName>
<ForeName>Jeffrey E</ForeName>
<Initials>JE</Initials>
<Identifier Source="ORCID">0000-0001-8388-6799</Identifier>
<AffiliationInfo>
<Affiliation>World Organization, Watkinsville, Georgia, USA jeff_gold@world.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Baumgartl</LastName>
<ForeName>William H</ForeName>
<Initials>WH</Initials>
<AffiliationInfo>
<Affiliation>Nevada Spine Center, Las Vegas, Nevada, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Okyay</LastName>
<ForeName>Ramazan A</ForeName>
<Initials>RA</Initials>
<AffiliationInfo>
<Affiliation>Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Licht</LastName>
<ForeName>Warren E</ForeName>
<Initials>WE</Initials>
<AffiliationInfo>
<Affiliation>Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fidel</LastName>
<ForeName>Paul L</ForeName>
<Initials>PL</Initials>
<Suffix>Jr</Suffix>
<Identifier Source="ORCID">0000-0001-8066-5763</Identifier>
<AffiliationInfo>
<Affiliation>Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Noverr</LastName>
<ForeName>Mairi C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo>
<Affiliation>Tulane University School of Medicine, New Orleans, Louisiana, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tilley</LastName>
<ForeName>Larry P</ForeName>
<Initials>LP</Initials>
<AffiliationInfo>
<Affiliation>VetMed Consultants, Inc., Santa Fe, New Mexico, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hurley</LastName>
<ForeName>David J</ForeName>
<Initials>DJ</Initials>
<AffiliationInfo>
<Affiliation>College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rada</LastName>
<ForeName>Balázs</ForeName>
<Initials>B</Initials>
<Identifier Source="ORCID">0000-0002-9742-4955</Identifier>
<AffiliationInfo>
<Affiliation>College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ashford</LastName>
<ForeName>John W</ForeName>
<Initials>JW</Initials>
<AffiliationInfo>
<Affiliation>Stanford University, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2020</Year>
<Month>11</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>mBio</MedlineTA>
<NlmUniqueID>101519231</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D022542">Measles-Mumps-Rubella Vaccine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C040901">rubella antibodies</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058345" MajorTopicYN="N">Asymptomatic Infections</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003289" MajorTopicYN="Y">Convalescence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D022542" MajorTopicYN="N">Measles-Mumps-Rubella Vaccine</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">MMR</Keyword>
<Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="Y">coronavirus</Keyword>
<Keyword MajorTopicYN="Y">immunization</Keyword>
<Keyword MajorTopicYN="Y">measles</Keyword>
<Keyword MajorTopicYN="Y">mumps</Keyword>
<Keyword MajorTopicYN="Y">rubella</Keyword>
<Keyword MajorTopicYN="Y">titers</Keyword>
<Keyword MajorTopicYN="Y">vaccines</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2020</Year>
<Month>11</Month>
<Day>21</Day>
<Hour>5</Hour>
<Minute>31</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2020</Year>
<Month>11</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2020</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">33219096</ArticleId>
<ArticleId IdType="pii">mBio.02628-20</ArticleId>
<ArticleId IdType="doi">10.1128/mBio.02628-20</ArticleId>
<ArticleId IdType="pmc">PMC7686805</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Science. 2016 Apr 22;352(6284):aaf1098</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">27102489</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2015 Jun 5;348(6239):aaa0698</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26045439</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2005 Jan 15;174(2):767-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15634897</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Front Mol Biosci. 2020 Jun 05;7:120</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32582766</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect Dis. 2008 Apr 1;197(7):950-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18419470</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Vaccine. 2018 Feb 1;36(6):818-826</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">29317117</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pediatrics. 2020 Jun;145(6):</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32179660</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Vaccin Immunother. 2020 Sep 1;16(9):2217-2218</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32501133</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Immunol. 2020 Jun;20(6):375-388</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32132681</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Immunol. 2020 Jun;20(6):335-337</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32393823</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Hum Genet. 2009 Jan;54(1):15-39</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19158813</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Expert Rev Anti Infect Ther. 2020 Oct;18(10):1005-1020</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32538209</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Vaccine. 2001 Feb 8;19(13-14):1727-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11166897</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Front Immunol. 2017 Jul 18;8:832</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">28769934</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>mBio. 2020 Jun 19;11(3):</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32561657</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2019 Jun 13;177(7):1827-1841.e12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">31178117</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Innate Immun. 2014;6(2):152-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24192057</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Microbiol. 2002 May;40(5):1733-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11980952</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Rev Med Virol. 2020 Nov;30(6):1-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32734714</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):166-172</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">30715451</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Public Health. 2015 Feb 22;15:175</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25886062</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trials. 2015 Apr 10;16:147</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25872531</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Vaccine. 2019 Jul 9;37(30):4164-4171</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">31151799</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2020 Jul 9;383(2):182-183</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32437597</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Med. 2008 Dec;121(12):1058-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19028201</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drugs. 2003;63(19):2107-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12962524</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Med Hypotheses. 2020 Oct;143:109849</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32480250</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2019 Nov 1;366(6465):599-606</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">31672891</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Vaccine. 2012 Nov 6;30(48):6918-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22959986</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Med Sci. 1980 Mar-Apr;279(2):95-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7386521</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Turquie</li>
<li>États-Unis</li>
</country>
<region>
<li>Californie</li>
<li>Géorgie (États-Unis)</li>
<li>Louisiane</li>
<li>Nevada</li>
<li>Nouveau-Mexique</li>
<li>Rhode Island</li>
</region>
<settlement>
<li>Stanford (Californie)</li>
</settlement>
<orgName>
<li>Université Stanford</li>
</orgName>
</list>
<tree>
<noCountry>
<name sortKey="Gold, Jeffrey E" sort="Gold, Jeffrey E" uniqKey="Gold J" first="Jeffrey E" last="Gold">Jeffrey E. Gold</name>
</noCountry>
<country name="États-Unis">
<region name="Nevada">
<name sortKey="Baumgartl, William H" sort="Baumgartl, William H" uniqKey="Baumgartl W" first="William H" last="Baumgartl">William H. Baumgartl</name>
</region>
<name sortKey="Ashford, John W" sort="Ashford, John W" uniqKey="Ashford J" first="John W" last="Ashford">John W. Ashford</name>
<name sortKey="Fidel, Paul L" sort="Fidel, Paul L" uniqKey="Fidel P" first="Paul L" last="Fidel">Paul L. Fidel</name>
<name sortKey="Hurley, David J" sort="Hurley, David J" uniqKey="Hurley D" first="David J" last="Hurley">David J. Hurley</name>
<name sortKey="Licht, Warren E" sort="Licht, Warren E" uniqKey="Licht W" first="Warren E" last="Licht">Warren E. Licht</name>
<name sortKey="Noverr, Mairi C" sort="Noverr, Mairi C" uniqKey="Noverr M" first="Mairi C" last="Noverr">Mairi C. Noverr</name>
<name sortKey="Rada, Balazs" sort="Rada, Balazs" uniqKey="Rada B" first="Balázs" last="Rada">Balázs Rada</name>
<name sortKey="Tilley, Larry P" sort="Tilley, Larry P" uniqKey="Tilley L" first="Larry P" last="Tilley">Larry P. Tilley</name>
</country>
<country name="Turquie">
<noRegion>
<name sortKey="Okyay, Ramazan A" sort="Okyay, Ramazan A" uniqKey="Okyay R" first="Ramazan A" last="Okyay">Ramazan A. Okyay</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000801 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000801 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidStanfordV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33219096
   |texte=   Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33219096" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidStanfordV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Tue Feb 2 21:24:25 2021. Site generation: Tue Feb 2 21:26:08 2021